Match!
Jonathan P. Caulkins
Carnegie Mellon University
316Publications
39H-index
5,069Citations
Publications 322
Newest
Source
#1Jonathan P. Caulkins (CMU: Carnegie Mellon University)H-Index: 39
#2Bryce Pardo (AN: RAND Corporation)H-Index: 1
Last.Beau Kilmer (AN: RAND Corporation)H-Index: 24
view all 3 authors...
Source
Various jurisdictions are legalising not just cannabis possession and use, but also large-scale commercial production, distribution and sale. Potential problems with that form of legalization raise questions about how best to implement a legalisation. This paper analyses the interests of the suppliers and regulators to help lawmakers and voters decide what over-arching architecture for legalisation might be prudent. In particular, it suggests banning for-profit companies and/or vesting regulator...
2 CitationsSource
Source
#1Thomas F. Babor (UConn: University of Connecticut)H-Index: 68
#2Jonathan P. Caulkins (CMU: Carnegie Mellon University)H-Index: 39
Last.John StrangH-Index: 62
view all 11 authors...
Source
#1Wayne Hall (UQ: University of Queensland)H-Index: 89
#2Daniel Stjepanović (UQ: University of Queensland)H-Index: 3
Last.Louisa Degenhardt (NDARC: National Drug and Alcohol Research Centre)H-Index: 91
view all 7 authors...
Summary We assess the current and describe possible future public health impacts of the legalisation of cannabis production, sale, and use in the Americas. First, we describe global patterns of cannabis use and their most probable adverse health effects. Second, we summarise evidence regarding the effectiveness of cannabinoids for medicinal use and describe approaches that have been used to regulate the use of medicinal cannabis and how these approaches might have affected medicinal and recreati...
4 CitationsSource
#1Jonathan P. Caulkins (CMU: Carnegie Mellon University)H-Index: 39
#2Bryce Pardo (AN: RAND Corporation)H-Index: 1
Last.Beau Kilmer (AN: RAND Corporation)H-Index: 24
view all 3 authors...
5 CitationsSource
#1Jonathan P. Caulkins (CMU: Carnegie Mellon University)H-Index: 39
#2Michelle L. Kilborn (AHS: Alberta Health Services)
ABSTRACTBackground: A number of countries are legalizing the supply of cannabis or are considering doing so. Beyond top-level design questions (e.g., who gets to supply and how will it be taxed?) l...
Source
#1Charles D. H. Parry (South African Medical Research Council)H-Index: 46
#2Bronwyn Myers (South African Medical Research Council)H-Index: 27
Last.Jonathan P. Caulkins (CMU: Carnegie Mellon University)H-Index: 39
view all 3 authors...
Source
#1Beau Kilmer (AN: RAND Corporation)H-Index: 24
#2Rosanna Smart (AN: RAND Corporation)H-Index: 2
Last.Jonathan P. Caulkins (CMU: Carnegie Mellon University)H-Index: 39
view all 4 authors...
Abstract Background Some countries allow physicians to prescribe pharmaceutical-grade diamorphine to dependent users who have previously undergone treatment but are still using street-sourced heroin; this is not allowed in the US. This study provides the first nationally representative US data concerning public support for prescribing diamorphine to dependent users. We also test the hypothesis that calling it “diamorphine” instead of “heroin” increases support for this approach. Methods The RAND...
Source
12345678910